Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma

European Journal of Cancer

Volumn 45, Issue 17, 2009, Pages 3074-3080

  Verhoeff, Joost J C ^a   Stalpers, Lukas J A ^a   Claes, An ^b   Hovinga, Koos E ^c   Musters, Gijsbert D ^a   Peter Vandertop, W ^a   Richel, Dick J ^a   Leenders, William P J ^b   van Furth, Wouter R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anti angiogenesis; Glioma; Irradiation; Orthotopic; Pegaptanib

Indexed keywords

IODINE 125; PEGAPTANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN RADIATION; CANCER CONTROL; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOXEMIA; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; SHAM PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; APTAMERS, NUCLEOTIDE; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350602717     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.08.004     Document Type: Article

References (42)

1. Salazar O.M., Rubin P., Feldstein M.L., and Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 5 (1979) 1733-1740
2. Giese A., Bjerkvig R., Berens M.E., and Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21 (2003) 1624-1636
3. van den Bent M.J., Hegi M.E., and Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer 42 (2006) 582-588
4. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
5. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A (1996) 2534-2539
6. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 (2002) 4368-4380
7. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
8. Eskens F.A., and Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?. Eur J Cancer 44 (2008) 2350-2356
9. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 (2000) 306-314
10. Leenders W.P., Kusters B., Verrijp K., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10 (2004) 6222-6230
11. Muldoon L.L., Soussain C., Jahnke K., et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25 (2007) 2295-2305
12. Chang C.H., Horton J., Schoenfeld D., et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer 52 (1983) 997-1007
13. Cao Y., Tsien C.I., Shen Z., et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23 (2005) 4127-4136
14. Nordal R.A., and Wong C.S. Molecular targets in radiation-induced blood-brain barrier disruption. Int J Radiat Oncol Biol Phys 62 (2005) 279-287
15. Wachsberger P., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9 (2003) 1957-1971
16. Williams J.R., Zhang Y., Zhou H., et al. Overview of radiosensitivity of human tumor cells to low-dose-rate irradiation. Int J Radiat Oncol Biol Phys 72 (2008) 909-917
17. Verhoeff J.J., Stalpers L.J., Coumou A.W., et al. Experimental iodine-125 seed irradiation of intracerebral brain tumors in nude mice. Radiat Oncol 2 (2007) 38
18. Eskens F.A., and Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42 (2006) 3127-3139
19. Mitchell P., Ellison D.W., and Mendelow A.D. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 4 (2005) 413-422
20. Ommaya A.K., Rubin R.C., Henderson E.S., et al. A new approach to the treatment of inoperable brain tumors. Med Ann Dist Columbia 34 (1965) 455-458
21. Chekenya M., Hjelstuen M., Enger P.O., et al. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J 16 (2002) 586-588
22. Brekke C., Lundervold A., Enger P.O., et al. NG2 expression regulates vascular morphology and function in human brain tumours. Neuroimage 29 (2006) 965-976
23. Hovinga K.E., Stalpers L.J., van Bree C., et al. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines - a clue to radioresistance?. J Neurooncol 74 (2005) 99-103
24. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
25. Ruckman J., Green L.S., and Beeson J. Et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273 (1998) 20556-20567
26. Schmidt P.G., Campbell K.M., Hinds K.D., and Cook G.P. PEGylated bioactive molecules in biodegradable polymer microparticles. Expert Opin Biol Ther 7 (2007) 1427-1436
27. Cloughesy T.F., Prados M.D., Wen P.Y., et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26 May 20 Suppl. (2008) 2010b
28. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787
29. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
30. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 (2004) 3731-3736
31. Claes A., Gambarota G., Hamans B., et al. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int J Cancer 122 (2008) 1981-1986
32. Williams K.J., Telfer B.A., Brave S., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 (2004) 8587-8593
33. Wild-Bode C., Weller M., Rimner A., Dichgans J., and Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61 (2001) 2744-2750
34. Tabatabai G., Frank B., Wick A., et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 61 (2007) 153-161
35. Bao S., Wu Q., Sathornsumetee S., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66 (2006) 7843-7848
36. Hochberg F.H., and Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 30 (1980) 907-911
37. van Nifterik K.A., Elkhuizen P.H., van Andel R.J., et al. Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: recurrence or second primary tumor?. J Neurosurg 105 (2006) 739-744
38. Narayana A., Kelly P., Golfinos J., et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110 (2009) 173-180
39. Gutin P.H., Iwamoto F.M., Beal K., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009)
40. Saidi A., Hagedorn M., Allain N., et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 125 (2009) 1054-1064
41. Park I., Tamai G., Lee M.C., et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 69 (2007) 381-389
42. Stadlbauer A., Prante O., Nimsky C., et al. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-l-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med 49 (2008) 721-729